News from orexigen therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 12, 2018, 01:08 ET Orexigen Therapeutics, Inc. Plans For Near-term Sale Using Structured Process Through Chapter 11 Of U.S. Bankruptcy Code

Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has elected to...

Nov 13, 2017, 15:01 ET Orexigen Therapeutics Announces Third Quarter 2017 Financial Results

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the third quarter ended September 30, 2017. Orexigen...

Nov 13, 2017, 07:08 ET Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt, Germany for Contrave in Latin America

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Merck KGaA,...

Oct 31, 2017, 18:57 ET Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2017 Financial Results on November 13, 2017

Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the third quarter of 2017 on Monday, November 13th after ...

Oct 13, 2017, 14:40 ET Orexigen Announces Favorable Decision from U.S. District Court in Patent Litigation, Confirming Exclusivity for Contrave Through 2030

Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced today that the United States District Court for the District of Delaware issued a ruling in...

Oct 12, 2017, 20:57 ET Orexigen Therapeutics to Provide Business Update at the 2017 BIO Investor Forum

Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced today that management will present at the 2017 BIO Investor Forum on Tuesday, October 17th, at...

Sep 26, 2017, 17:13 ET Orexigen Therapeutics Launches Next Stage of a Dynamic Campaign to Educate Consumers About Contrave®

Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced today the launch of the next stage of "Brains Behind Weight Loss," the Company's national...

Sep 13, 2017, 17:15 ET Orexigen Therapeutics to Provide Business Update at the 2017 Cantor Fitzgerald Global Healthcare Conference

Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced today that management will present at the 2017 Cantor Fitzgerald Global Healthcare Conference on ...

Aug 29, 2017, 09:25 ET Orexigen Therapeutics to Speak at Upcoming Investor Conferences

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are...

Aug 08, 2017, 16:01 ET Orexigen Therapeutics Announces Second Quarter 2017 Financial Results

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the second quarter ended June 30, 2017. "Our...

Aug 07, 2017, 07:10 ET Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and Austria

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Cheplapharm...

Jul 26, 2017, 08:50 ET Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl extended release) to Egypt

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Biologix FZCO...

Jul 25, 2017, 16:30 ET Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results on August 8, 2017

Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the second quarter 2017 on Tuesday, August 8th after the ...

Jul 10, 2017, 12:01 ET Orexigen Announces Presentation of Data for OREX-1019 and OREX-1038, Preclinical Candidates for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug Addiction

Orexigen Therapeutics, Inc. (NASDAQ: OREX) announced today that the Company will present oral and poster presentations on OREX-1019 and OREX-1038 at...

May 16, 2017, 16:10 ET Orexigen Announces Activities at European Congress on Obesity 2017

Orexigen Therapeutics, Inc. (NASDAQ: OREX) announced today that the company will present two oral presentations on naltrexone HCl / bupropion HCl,...

May 09, 2017, 16:01 ET Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the first quarter ended March 31, 2017. "During the...

May 02, 2017, 16:57 ET Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch Healthcare Conference

Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced today that management will present at the 2017 Bank of America Merrill Lynch Healthcare...

May 02, 2017, 03:00 ET Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic Countries

Orexigen Therapeutics, Inc. (NASDAQ:OREX) today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Navamedic AB, an...

Apr 25, 2017, 18:05 ET Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on May 9, 2017

Orexigen Therapeutics, Inc. (NASDAQ: OREX) will announce corporate and financial results for the first quarter 2017 on Tuesday, May 9th after the...

Apr 25, 2017, 01:55 ET Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada

Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company helping to improve the health and lives of patients struggling with weight...

Mar 28, 2017, 16:21 ET Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the fourth quarter and year ended December 31, 2016....

Mar 27, 2017, 18:03 ET Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Bruno Farmaceutici S.p.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Italy

Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Bruno...

Mar 07, 2017, 19:56 ET Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017

Orexigen Therapeutics, Inc. (NASDAQ: OREX) will announce corporate and financial results for the fourth quarter and full year 2016 on Tuesday, March...

Feb 07, 2017, 15:40 ET Orexigen Therapeutics to Speak at Upcoming Investor Conferences

Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are...

Jan 25, 2017, 06:40 ET Orexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Partnership with Laboratorios Farmacéuticos Rovi, S.A.

Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that Laboratorios Farmacéuticos Rovi, S.A. (ROVI) has launched Mysimba in Spain. Mysimba...